Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShares IssuedShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Long-Term Debt Repayments (2023 - 2024)

Regen BioPharma (RGBPP) has disclosed Long-Term Debt Repayments for 2 consecutive years, with $65799.0 as the latest value for Q4 2024.

  • On a quarterly basis, Long-Term Debt Repayments rose 241.5% to $65799.0 in Q4 2024 year-over-year; TTM through Dec 2025 was $65799.0, a 35.68% decrease, with the full-year FY2025 number at $194599.0, up 2045.99% from a year prior.
  • Long-Term Debt Repayments was $65799.0 for Q4 2024 at Regen BioPharma, up from $36500.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $65799.0 in Q4 2024 to a low of -$46500.0 in Q4 2023.